Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(75%)
Terminated
1(25%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

3

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Terminated(1)

Detailed Status

Recruiting2
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
3
Success Rate
0.0%
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

terminated125%
recruiting250%
active_not_recruiting125%

Recent Activity

3 active trials
Showing 4 of 4
recruitingphase_1

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

NCT06930755
recruitingphase_1

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

NCT06931626
active_not_recruitingphase_1

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

NCT04910022
terminatedphase_1

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

NCT04182516

Clinical Trials (4)

Showing 4 of 4 trials
NCT06930755Phase 1

Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer

Recruiting
NCT06931626Phase 1

Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer

Recruiting
NCT04910022Phase 1

Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma

Active Not Recruiting
NCT04182516Phase 1

Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4